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Summary Tumour radioiodine concentration has been compared with serum thyroglobulin (Tg) and, in a
few cases, with tumour complement of thyrotrophin receptors in patients with differentiated thyroid
carcinoma.
All tumours examined possessed TSH receptors. In most the complement was similar to that of normal
thyroid tissue although all but one of the tumours had no detectable 1311 concentration in vivo even with
excess TSH stimulation.
Elevated serum Tg (patient taking T4 in suppressive dose) was generally associated with tumours which had
1311 concentrating function when stimulated by excess TSH. Some patients, however, had high serum Tg
concentration but only low or indetectable tumour 1311 uptake.
We conclude that (a) measurement of tumour TSH receptor complement is unlikely to be useful in clinical
management as tumours which do not significantly concentrate 1311 in vivo may have a normal TSH receptor
complement and (b) the capacity to secrete Tg is usually associated with 1311 concentration but quantitatively
the relationship varies considerably between tumours.
For the effective use of 1311 in the treatment of
thyroid cancer, adequate organification of the
radioisotope by tumour tissue is essential. Most
thyroid tumours even though differentiated, are
usually nonfunctional initially when normal thyroid
tissue is still present. Subsequently a tumour often
develops the ability to concentrate 1311 although
usually only if stimulated by supranormal levels of
TSH (Edmonds et al., 1977). Unfortunately there is
no satisfactory way of predicting at an early stage
whether a particular tumour will eventually develop
sufficient capacity for 1311 concentration. Thyro-
globulin production and the presence of TSH
receptors on the plasma membranes are two
properties indicative of potentially functioning
tissue and we have compared these characteristics
with the radioiodine uptakes observed during
treatment.
Materials and methods
All patients attended the Thyroid Clinic in the
Department of Radiotherapy and Oncology at
University College Hospital and were subsequently
on long term follow up. The treatment protocol
was initial thyroidectomy with removal of as much
tumour as possible followed by therapy and test
doses of 1311 as previously described (Edmonds et
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al., 1977). Patients received T4 daily in amount
usually 200-300,ug sufficient to suppress the TSH
response to TRH. The T4 was stopped 4 weeks
before an 1311 dose. Treatment and test doses of
5.5GBq (lOmCi) and 185MBq (5mCi) of 1311
respectively were used. A whole body profile scanner
based on the design of Corbett et al. (1956) but
having a sodium iodide scintillator with a
rectangular slit collimator perpendicular to the long
axis of the patient was used to estimate the amount
of 1311 concentrated at any site. Scanning by
gamma camera was also carried out over
appropriate regions. Measurements were done at 2
and at 5 to 7 days after the 1311 administration; the
delayed measurements allowed excretion of 1311_
iodide so that low levels of functional activity could
be determined. The lower limit of sensitivity of
localized concentrations detectable was 0.2-0.8 MBq
(5-20 uCi).
Fresh human thyroid tissue, tumour and/or
lymph nodes were obtained at operation and
subsequently classified into their pathological type
on the basis of histological examination (kindly
performed in the Department of Pathology,
University College, London, School of Medicine).
Specimens were, in addition, placed on ice and
membrane extracts prepared which were later used
for measurement of TSH binding capacity and for
assessment of binding characteristics: the methods
were as those previously described in detail
(Kermode & Thompson, 1980; Kermode et al.,
1981). Normal thyroid tissue (normal on the basis
of histology) was obtained where feasible by
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dissecting it from abnormal regions in the
specimens removed from these and other patients.
Most of our studies have been with bovine TSH
(bTSH) but a small amount of human TSH has
also been available to allow us to compare average
binding percentages. Serum thyroglobulin (Tg),
measured using a double antibody radioimmuno-
assay, was determined periodically, usually every 6
months or yearly in all patients attending the
Clinic. Antiserum to human Tg was raised in
rabbits and used at a final dilution of 1 in 105.
Donkey anti-rabbit serum was used as the second
antibody. Fifty pl of 125I-Tg was added to tubes
containing 100p1 of serum or standard and 110p1
of antiserum. Twenty-four hours after adding the
label, tubes were centrifuged, the supernatant
removed and precipitates counted. The Tg assay
was sensitive to a limit of about 5 pg1-'. In
individuals without thyroid disease, Tg infrequently
exceeded 50pgI-1.
The results are given as mean with standard
deviation. The expression of binding capacity in
terms of g.equiv (gram equivalent of membranes)
relates to an amount of membranes which would be
obtained from 1 g (wet weight) of chopped tissue
(Smith & Hall, 1974).
Results
TSH binding
The tumours of all the six patients with
differentiated cancer had demonstrable specific
binding of 1251-labelled bTSH and, on most, the
binding percentage differed little from the normal
value (Table I). The lowest binding was in a
tumour of patient 5 but this tumour was also less
well differentiated than the others. Of the six
patients studied, one (la, b, Table I and Figure 1)
provided two specimens, the first obtained at the
initial thyroidectomy, the second two and a half
years later when recurrent lymph nodes were
removed. The two specimens had similar histological
appearance and bTSH binding.
The binding of human TSH (hTSH) was also
examined in all of the samples. The general pattern
of variation was similar but the binding percentage
was considerably less. Thus for the normal tissues
average binding was 33.6+9.9% using bTSH
compared with 7.9+3.2% using hTSH; for the
differentiated tumours, binding averaged 30+7.1%
for bTSH compared with 8.2+2.1% for hTSH.
Similar differences in binding have been previously
Table I Binding characteristics of the TSH receptor, tumour 1311 concentration and serum thyroglobulin (Tg)
concentrations in patients with differentiated thyroid cancer
Binding characteristics
Tumour b TSH Capacity 131I Serum Tg
Sex & pathologya binding (pmolq-1 equiv) Affinity concentration on T4 off T4
Patient age (y) (TNM stage) (% age) (membranes) (Imol-l x 0-9) (% dose g 1) (jg! 1)
la F 20 Papillary (p) 38.1 2.08 6.9
b Papillary (In) 46.9 1.83 7.9 0.03 >300 >300
(210)
2 M 67 Papillary (p) 56.1 3.90 4.5 Uncertain <10 44
(200)
3 F 19 Papillary (In) 38.7 3.39 4.4 <10 <10
(210)
4 F 39 Papillary (In) 25.4 0.89 5.4 20 17
(210) Undetectable
5 M 60 Follicular (p) 19.2 0.13 25.9 <10 22
(201)
6 M 49 Follicular (In) 41.7 1.85 5.7 J >300 >300
(211)
Normal
thyroid 20-67 33.6 0.99 11.2
(10) +9.9 +0.50 +5.4
a131I concentration in tumour, measured at 5 days after administration of the activity, was that observed when
T4 had been discontinued and plasma TSH concentration exceeded 30mU1-'. The source of tumour tissue is given
in parentheses: p=primary; In=lymph node. The TNM classification (UICC) for each patient is also included.RECEPTORS THYROGLOBULIN AND FUNCTION IN THYROID CANCERS 539
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Concentration of 131I by tumour
None of the tumours or metasta
patients (Table I) had detectable cc
1311 initially when the normal thyr(
and when plasma TSH levels were within the nor-
mal range (<4mUI-'). Following thyroidectomy
and withdrawal of any T4 supplement, supranormal
levels of plasma TSH were obtained being
>30mU l in all patients. Only in patient 1,
however, did detectable concentration of 131I in
tumour tissue then occur, localized in metastatic
lymph nodes in the neck. None of the other patients
developed detectable 131I uptake in remaining
tumour (Table I). The function of tumour tissue of
patient 2 could not be determined at supranormal
TSH stimulation as operative removal was
complete.
Thyroglobulin secretion
These measurements, recorded in Table I, were
made in the period just before 131I concentrating
function was determined. All measurements were
made after surgical removal of the thyroid and
1982 1983 primary tumour, and after an initial 131I therapy
ate (y) dose to ablate any normal thyroid remnant. In two
ration during the patients (1 and 6 of Table I), serum Tg was very
patient 1 (Table high and unaffected by T4. Surgical removal of the
(roidectomy and lymph node remnant after repeated 1311 therapy,
the right side of abolished both 1311 concentration and Tg secretion
Radioiodine was (Figure 1). The other patients had undetectable
ant on the right serum Tg when taking T4 but three (patients 2, 4
[lowing complete and 5) had some increase when T4 was withdrawn.
During the period of the present study, 156
patients were attending the follow up clinic, 33 of
whom had recurrent tumours in the thyroid bed or
I from various in metastases particularly to lymph nodes, bone and
yroid (Kermode lung. Seven of these were follicular and 26 papillary
tumours. The serum Tg measurement in these
;y were assessed patients was examined in relation to the 1311
n of binding of concentrating function of the tumours (Figure 2).
fincreasing con- Concentration of 1311 was undetectable in 8 (23%)
H. The binding of the tumours but the tumours of two patients
le binding site' secreted considerable amounts of Tg. In the
giving a linear remaining patients, although both 1311 concen-
There was con- tration and Tg secretion were present, the extent of
ns (Table I) but each function varied considerably' from one
idual (patient 5) individual to another (Figure 2); several patients
red with normal with high serum Tg concentration had tumours
resented related which concentrated relatively little 1311. There were
mbrane protein no evident features, clinical or histological, which
se specimens by could be correlated with this variability.
l). The pattern
was essentially
to membrane
ses of the six
mncentrations of
oid was present
Discussion
A number of studies of TSH receptors have shown
that they can be identified in differentiated thyroid
tumours although uniformly nonfunctioning
tumours such as medullary and anaplastic thyroid
carcinomata have none or very few TSH receptors
(Takahashi et al., 1978; Carayon et al., 1980; Abe et
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Figure 2 The relationship in 33 patients of 1311
concentration by tumour, measured at 5 days after
administration of the activity, to the serum Tg
concentration. Five patients had neither detectable
1311 concentration nor serum Tg.
al., 1981). On the other hand, papillary and
follicular carcinomata vary considerably in their
1311 concentrating ability. Radioiodine
concentrating function in vivo and TSH receptor
complement have not been correlated and it was
the particular object of the present study to make
this comparison. All the differentiated tumours of
our patients possessed clearly demonstrable TSH
receptors. The tumour of patient 5 showed the
poorest differentiation and was also nonfunctioning.
It also had the lowest complement of receptors. Of
the other tumours, although only that of patient 1
had measurable 1311 concentrating function, all had
similar and apparently normal receptor
complements. Patient 1 has been satisfactorily
treated with several doses of 131I but in none of the
other patients did this prove possible. In practice,
therefore, measurement of TSH receptor
complement as a guide to potential tumour
function, and thereby to possible future 1311
therapy, is unlikely to be of value. The method does
not appear to identify potentially functioning
tumours any better than the guide provided by
histological appearance.
The other aspect of thyroid cellular function,
namely Tg production, was investigated by the
serum Tg measurements. The best indicator of
tumour production of Tg is probably obtained
when serum Tg is measured at the time the patient
is taking full doses of T4 since Tg secretion from
any normal thyroid remnant should then be
completely suppressed (Fui et al., 1979). On this
basis, the patients 1, 4 and 6 had evidence of
tumour Tg production. In patient 1 her high level
of serum Tg was associated with a tumour which
concentrated 131I relatively well although, as
indicated by % of 131I dose concentrated g-1 tissue,
the concentration was low compared with that of
normal thyroid tissue despite enhanced TSH
stimulation. In this patient, both aspects of thyroid
cell function were evidently present. By contrast in
the other two patients, 4 and 6, no 131I concen-
trating function was detectable in the tumours
although the TSH receptors were well within the
normal range in the tumours of these patients.
Studies of the iodine content of Tg derived from
tumour tissue have shown that it may be very low
(Schneider et al., 1983) an observation which,
together with the present results, indicates that the
retention of Tg secreting activity by the tumour
does not necessarily mean that the tumour will
concentrate iodine well.
In conclusion, our observations show that the
presence of a normal complement of TSH receptors
does not indicate that iodine concentration will
occur even when plasma TSH levels are much
elevated. The mediating factors between the TSH-
receptor complex and iodide trapping and organifi-
cation are presumably inadequate in some tumour
cells. Secretion of Tg by tumour tissue, in contrast
to normal thyroid tissue, appears to be largely
independent of TSH control. Moreover con-
siderable Tg secretion may occur from some
tumours which have little or no functional iodine
concentrating mechanism even though stimulated
by high plasma TSH concentrations. Nevertheless,
in the majority of patients, the capacity of the
tumour to secrete Tg does appear to indicate that it
will also concentrate iodine although the relation-
ship between these two cellular functions varies
considerably from one tumour to another.
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